No-Synthase Activity in Patients with Coronary Heart Disease Associated with Hypertension of Different Age Groups/ Aktivnost no-sintaze kod pacijenata s koronarnom bolešću srca povezanom s hipertenzijom kod različitih starosnih grupa

Open access

Summary

Background: Coronary heart disease is the leading cause of death and disability worldwide. Hypertension is a major independent risk factor for the development of CHD. Abnormalities in NO generation or activity have been proposed as a major mechanism of CHD. The purpose of this article is to determine the activity of eNOS and iNOS in patients with isolated CHD and CHD associated with HT of different age groups.

Methods: Fifty patients with isolated CHD and 42 patients with CHD associated with HT were enrolled in this study. NOS activity was determined by nitrite anion formed in the reaction.

Results: A statistically significant increase in iNOS activity is observed in elderly donors. In patients with isolated coronary heart disease cNOS activity is statistically significantly reduced with respect to the control group. The reduction of enzymatic activity of cNOS is more expressed in elderly patients than in middle-aged patients with coronary heart disease. Alterations in eNOS activity are more expressed in patients with coronary heart disease associated with hypertension than in patients with isolated coronary heart disease. Against the background of cNOS inhibition in the patients, a sharp increase in iNOS activity is observed.

Conclusions: It has been shown that disturbance of endo - thelial function in patients with coronary heart disease associated with hypertension is characterized by reduced endothelial NO synthesis by cNOS and increased systemic NO synthesis due to increased iNOS activity. It has been found that the lack of endothelial NO and hyperproduction of »harmful« NO by iNOS are more expressed in elderly patients.

1. Gouvinhas C, Severo M, Azevedo A, Lunet N. World - wide patterns of ischemic heart disease mortality from 1980 to 2010. Int J Cardiol 2013; 170: 309-14.

2. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. Common values in assessing health outcomes from disease and injury: Disability weights measurement study for the global burden of disease study 2010. Lancet 2012; 380: 2129-43.

3. De Backer GG. The global burden of coronary heart disease. Medicographia 2009; 31: 343-8.

4. Reid CM, Owen AJ, Freedman B. Coronary artery disease epidemics: not all the same. Medicographia 2014; 36: 11-8.

5. Rosendorff C, Black H, Cannon C, Gersh B, Gore J, Izzo J, et al. Treatment of hypertension in the prevention and management of ischemic heart disease.

Circulation 2007; 115: 2761-88.

6. Tang EH, Vanhoutte PM. Endothelial dysfunction: a stra tegic target in the treatment of hypertension? Pflugers Arch 201; 459: 995-1004.

7. Dharmashankar K, Widlansky ME. Vascular endothelial function and hypertension: insights and directions. Curr Hypertens Rep 2010; 12: 448-55.

8. Dudzinski DM, Igarashi J, Greif D, Michel T. The regulation and pharmacology of endothelial nitric oxide synthase.

Annu Rev Pharmacol Toxicol 2006; 46: 235-76.

9. Deng XS, Deitrich RA. Ethanol metabolism and effects: nitric oxide and its interaction. Curr Clin Pharmacol 2007; 2: 145-53.

10. Gladwin MT, Schechter AN, Kim-Shapiro DB, Patel RP, Hogg N, Shiva S, et al. The emerging biology of the nitrite anion in signaling, blood flow and hypoxic nitric oxide homeostasis. Nat Chem Biol 2005; 1: 308-14.

11. Suvorava T, Stegbauer J, Thieme M, Pick S, Friedrich S, Rump LC, et al. Sustained hypertension despite endothelial-specific eNOS rescue in eNOS-deficient mice. Bio chem Biophys Res Commun 2015; 458: 576-83.

12. Oliveira-Paula GH, Lacchini R, Tanus-Santos JE. In du - cible nitric oxide synthase as a possible target in hypertension.

Curr Drug Targets 2014; 15: 164-74.

13. Guevara I, Iwanejko J, Dembin´ska-Kie} A, Pankiewicz J, Wanat A, Anna P, et al. Determination of ni trite/ ni trate in human biological material by the simple Griess reaction. Clinica Chimica Acta 1998; 274: 77-88.

14. Angeline T, Isabel W, Tsongalis GJ. Endothelial nitric oxide gene polymorphisms, nitric oxide production and corona ry artery disease risk in a South Indian population.

Experimental and Molecular Pathology 2010; 89: 205-8.

15. Abolhalaj M, Amoli MM, Amiri P. eNOS Gene Variant in Patients with Coronary Artery Disease. Journal of Bio - markers 2013; 34: 1-6.

16. Kato N, Sugiyama T, Morita H, Nabika T, Kurihara H, Yamori Y, et al. Lack of evidence for association between the endothelial nitric oxide synthase gene and hypertension. Hypertension 1999; 33: 933-6.

17. Cvetkovi} T, Veli~kovi}-Radovanovi} R, Stojanovi} D, Stefanovi} N, Ignjatovi} A, Stojanovi} I, Sladojevi} N, Pavlovi} D. Oxidative and nitrosative stress in stable renal transplant recipients with respect to the immunosuppression protocol - differences or similarities? J Med Biochem 2015; 34: 295-303.

18. Rush JW, Denniss SG, Graham DA.Vascular nitric oxide and oxidative stress: determinants of endothelial adaptations to cardiovascular disease and to physical activity. Can J Appl Physiol 2005; 30: 442-74.

19. Desjardins F, Balligand JL. Nitric oxide-dependent endo thelial function and cardiovascular disease. Acta Clin Belg 2006; 61: 326-34.

20. Piech A, Massart PE, Dessy C, Feron O, Havaux X, Morel N, et al. Decreased expression of myocardial eNOS and caveolin in dogs with hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 2002; 282: H219-H231.

21. Onat A, Sari I, Hergenç G, Yazici M, Uyarel H, Can G, et al. Predictors of abdominal obesity and high susceptibility of cardiometabolic risk to its increments among Turkish women: a prospective population-based study. Metabo lism 2007; 56: 348-56.

22. Seoudi OH. Allelic polymorphism in the endothelial nitric oxide synthase gene in coronary artery diseases. Egyptian Journal of Hospital Medicine 2009; 37: 700-8.

23. Apykhtina EL, Kotsuruba AV, Korkach YuP. Modulative effect of serratula coronata extract on nitric oxide meta - bolism in aorta tissues of rats under lead into xication. Ukrainian Biochemical Journal 2007; 5: 204-11.

24. Kulchytsky DC. System nitric oxide and age. Bukovinian Medical Herald 2005; 9: 143-4.

25. Csiszar A, Ungvari Z, Edwards JG, Kaminski P, Wolin MS, Koller A, et al. Aging-induced phenotypic changes and oxidative stress impair coronary arteriolar function. Circ Res 2002; 90: 1159-66.

26. Santhanam L, Lim HK, Lim HK, Miriel V, Brown T, Patel M, et al. iNOS-dependent S-nitrosylation and activation of arginase 1 contributes to age related endothelial dysfunction. Circ Res 2007; 101: 692-702.

27. Stankovi} S, A{anin M, Majki}-Singh N. The pharmacogenetics of cardiovascular drugs. J Med Biochem 2014; 33: 71-81.

28. Gkaliagkousi E, Ritter J, Ferro A. Platelet-derived nitric oxide signaling and regulation. Circ Res 2007; 101: 654-62.

29. Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M, Aretz TH, Hajjar R, et al. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation 2001; 104: 448-54.

30. Thomas DD, Ridnour LA, Isenberg JS, Flores-Santana W, Switzer CH, Donzelli S, et al. The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med 2008; 45: 18-31.

31. Lubos E, Handy DE, Loscalzo J. Role of oxidative stress and nitric oxide in atherothrombosis. Front Biosci 2009; 13: 5323-44.

Journal of Medical Biochemistry

The Journal of Society of Medical Biochemists of Serbia

Journal Information


IMPACT FACTOR 2017: 1.378
5-year IMPACT FACTOR: 0.704



CiteScore 2017: 1.05

SCImago Journal Rank (SJR) 2017: 0.307
Source Normalized Impact per Paper (SNIP) 2017: 0.532

Cited By

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 230 229 13
PDF Downloads 74 74 8